A phase II study of Erlotinib plus Pemetrexed for Non Small Cell Lung Cancer with T790M negative previously treated with EGFR-TKI

INTERVENTION: A combined chemotherapy of Erlotinib plus Pemetrexed CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: Disease control rate SECONDARY OUTCOME: Response rate; Overall survival; Progression free survival; Safety INCLUSION CRITERIA: 1) Histologically or cytologically confirmed non‐small cell lung cancer 2) Stage IIIB/IV or postoperative recurrence NSCLC 3) Patients with EGFR mutation (exon 18 or 19 or 21) 4) Patients aged 20 years or older. 5) Previously treated EGFR‐TKI 6) Previously treated no or one chemotherapy regimen after EGFR‐TKI 7) Patients who do not possess T790M 8) ECOG performance status of 0‐2 9) Measureable region evaluable according to the RECIST(ver.1.1) 10) Expected to be observed for at least 2 to 4 weeks in a hospital or in a comparable institution after the initiation of this treatment 11) Adequate organ function. 12) More than 4 weeks after the last chemotherapy 13) Patients who are considered to survive for more than 3 months 14) Written informed consent from the patient